Evidence map›Paper›PMID 34165174›Full record

ArticleOncology reports2021

Endothelin-1 induces changes in the expression levels of steroidogenic enzymes and increases androgen receptor and testosterone production in the PC3 prostate cancer cell line.

María José Torres, Fernanda López-Moncada, Daniela Herrera, Sebastián Indo, Alejandro Lefian, Paola Llanos, Julio Tapia, Enrique A Castellón, Héctor R Contreras

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Endothelin-1 signaling in the kidney: recent advances and remaining gaps.American journal of physiology. Renal physiology · 2025
    Review
  2. Review
  3. Alpha-Lipoic Acid-Mediated Inhibition of LTBCurrent therapeutic research, clinical and experimental · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

María José TorresDepartment of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Fernanda López-MoncadaLaboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Faculty of Medicine, University of Chile, Santiago 838 0000, Chile.
Daniela HerreraDepartment of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Sebastián IndoDepartment of Medical Technology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Alejandro LefianDepartment of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Paola LlanosInstitute for Research in Dental Sciences, Faculty of Dentistry, University of Chile, Santiago 8380544, Chile.
Julio TapiaInstitute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Enrique A CastellónDepartment of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
Héctor R ContrerasDepartment of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile.
University of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelin‑1 (ET‑1) is involved in the regulation of steroidogenesis. Additionally, patients with castration‑resistant prostate cancer (PCa) have a higher ET‑1 plasma concentration than those with localized PCa and healthy individuals. The aim of the present study was to evaluate the effect of ET‑1 on steroidogenesis enzymes, androgen receptor (AR) and testosterone (T) production in PCa cells. The expression levels of endothelin receptors in prostate tissue from patients with localized PCa by immunohistochemistry, and those in LNCaP and PC3 cells were determined reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. Furthermore, the expression levels of ET‑1 were determined in LNCaP and PC3 cells by RT‑qPCR and western blotting. The ET‑1 receptor activation was evaluated by intracellular calcium measurement, the expression levels of AR and enzymes participating in steroidogenesis [cytochrome P450 family 11 subfamily A member 1 (CyP11A1), cytochrome P450 family 17 subfamily A member 1, aldo‑keto reductase family member C2 and 3β‑hydroxysteroid dehydrogenase/isomerase 2 (3β HSD2)] were determined by western blotting and T concentration was determined by ELISA using PC3 cells. The present results revealed higher expression levels of endothelin A receptor (ET

Indexed as

3-Hydroxysteroid DehydrogenasesAgedAged, 80 and overCell Line, TumorCholesterol Side-Chain Cleavage EnzymeEndothelin-1HumansMaleMiddle AgedNeoplasm GradingPC-3 CellsProstatic NeoplasmsReceptor, Endothelin AReceptor, Endothelin BReceptors, AndrogenTestosterone3-Hydroxysteroid DehydrogenasesAR protein, humanCholesterol Side-Chain Cleavage EnzymeEDNRA protein, humanEDNRB protein, humanEndothelin-1Receptor, Endothelin AReceptor, Endothelin BReceptors, AndrogenTestosteroneandrogen receptorcastration-resistant prostate cancerendothelin-1endothelin receptorsteroidogenesis

Identifiers

PMID34165174
PMCPMC8261198
OpenAlexW3174450233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.